EGFR and HER2 mutations and ALK rearrangement are known to be related to lung cancer in never-smokers, while KRAS, BRAF and PIK3CA mutations are typically observed among smokers. There is still debate surrounding whether never-smokers exposed to passive smoke exhibit a "smoker-like" somatic profile compared with unexposed never-smokers. Passive smoke exposure was assessed in the French BioCAST/IFCT-1002 never-smoker lung cancer cohort and routine molecular profiles analyses were compiled. Of the 384 patients recruited into BioCAST, 319 were tested for at least one biomarker and provided data relating to passive smoking. Overall, 219 (66%) reported having been exposed to passive smoking. No significant difference was observed between mutation frequency and passive smoke exposure (EGFR mutation: 46% in never exposed versus 41% in ever exposed; KRAS: 7% versus 7%; ALK: 13% versus 11%; HER2: 4% versus 5%; BRAF: 6% versus 5%; PIK3CA: 4% versus 2%). We observed a nonsignificant trend for a negative association between EGFR mutation and cumulative duration of passive smoke exposure. No association was found for other biomarkers. There is no clear association between passive smoke exposure and somatic profile in lifelong, never-smoker lung cancer.
No impact of passive smoke on the somatic profile of lung cancers in never-smokers.
Eur Respir J. 2015;45(5):1415-25.
MeSH terms: Adenocarcinoma; Aged; Anaplastic Lymphoma Kinase; Biomarkers; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Female; France; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Phosphatidylinositol 3-Kinases; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Smoking; Surveys and Questionnaires; Tobacco Smoke Pollution